Lead Product(s): Undisclosed
Therapeutic Area: Vaccines Product Name: Undisclosed
Highest Development Status: Discovery Platform Product Type: Vaccine
Partner/Sponsor/Collaborator: Ligand Pharmaceuticals
Deal Size: $516.0 million Upfront Cash: Undisclosed
Deal Type: Acquisition August 10, 2020
Acquisition of Pfenex is expected to contribute a range of strategic benefits to Ligand like access to a proprietary, protein expression technology, utilized in various commercial and development-stage biopharmaceutical programs. Versatile operating business and among others.